A top official told lawmakers on Thursday that the Biden administration is “in discussion” to make sure it can get booster COVID-19 shots. This has been announced as drug makers are postponing their progress in developing additional shots, which are designed to enhance the body’s immune response after the initial dose.
For the response of COVID-19 to the administration, Chief Science Officer Dr. David Kessler said, “We are in the discussion right now, making sure that we can secure those vaccines for promotion or variants. Right now we are in that process.” told Select Subcommittee on House Coronovirus Crisis.
Federal health officials and drug makers have said for months that booster shots would be needed at some point, though it is not yet clear when that will happen. Shots will likely be similar to the original version of vaccines, but can be administered in different doses or tweaked to avoid variants.
Kessler cautioned that “no decision” had reached the strategy of how immunity from vaccinations operates, citing how long vaccines last. Recent studies from Pfizer And Moderna It is suggested that their COVID-19 shots remain effective for at least 6 months.
“With many vaccines, we understand that at a certain point in time we need to be promoted, whether it’s 9 months, 12 months. And we’re preparing for that,” Kessler said.
The companies behind the trio of COVID-19 vaccines currently used in the United States have stated that they are chasing additional shots.
Pfizer CEO Albert Borla said on Thursday, “A third dose will be needed, somewhere between 6 to 12 months. And then there will be an annual revision. Virtual event Hosted by CVS Health.
in February, Pfizer announced It was launching a study with its German partners BioNTech to examine a third dose of their vaccine, with participants delivery 6 to 12 months after completing their first two doses. Modern announced There are plans to test an additional booster shot of its own at the end of January.
“We believe that especially high-risk people should get a drop in growth, and we want to make sure we have the best possible boost,” Modern CEO Stefan Bancel told Yahoo finance On Wednesday, he said he expects a “boost market” as the government works to secure booster doses.
National institute of health Also announced In late March it was beginning initial trials in a version of the modern Trika, targeting the first-ever B.1.351 virus variant seen in South Africa. Pfizer is working on a possible version of its vaccine for B.1.351, although the drug manufacturer said earlier this month Its shots appeared highly effective against mutant stress.
Johnson & Johnson was actively recruited for this Study of “ENSEMBLE 2” To evaluate a two-dose diet instead of your current single-shot vaccine. But testing has been halted by the company over concerns of rare clotting incidents currently being investigated by the CDC and FDA.
The data from all three tests would have to be examined by the FDA, which was prescribed Updated guidelines To authorize additional doses of vaccines earlier this year. Smaller peaks will also need to be supported by some clinical research for the next generations of COVID-19 vaccines, although in smaller trials than the vast majority of people in early trials.
The director of the FDA’s Center for Biologics Evaluation, Drs. Peter Marks and Director said, “Maybe after doing this we will do three or four times, we will see everything and if everything seems consistent, we can move towards a model like influenza.” Research, Said in february.
But finding a place for a booster dose can prove difficult. Government accountability office Warned this week The use of the Defense Production Act to prioritize COVID-19 vaccine production has increased capacity for other important drugs, including the seasonal flu vaccine.
Making the next round of supplements for Americans could further delay global vaccination efforts that are already facing WHO Director General Drs. Tedros Adenom Ghebayeus described as “severe supply bottlenecks”.
While the US has already managed about 200 million doses 2 adults in about 1 With at least one shot, the World Health Organization Warned on wednesday Less than 0.2% of the global supply of vaccines had reached low-income countries.
“Global manufacturing capacity and supply chains are not sufficient to deliver vaccines quickly and evenly to where they are most needed. More money is needed, but this is only part of the solution. If buying a vaccine Money doesn’t help if it’s not for, “Ghebreyus said.